New combo therapy targets melanoma in the brain

NCT ID NCT05704647

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This phase 2 trial is testing whether combining two immunotherapy drugs, nivolumab and relatlimab, can help control melanoma that has spread to the brain. About 30 adults with active brain metastases will receive the drugs by IV. Researchers will monitor side effects and how well the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and relatlimab (immunotherapy drugs given by IV)
What this could lead to: If it works, this could offer a new treatment option for melanoma that has spread to the brain, helping control the disease.
What could go wrong: This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The drugs can cause immune-related side effects, and there is no guarantee they will shrink brain tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA (SKIN)

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.